Company news
Pharmadrug, Inc. news in 2024
Pharmadrug, Inc.'s news releases, calls and decks from 2024, newest first.
PharmaDrug Announces Issuance of Debenture Units
November 15, 2024
PharmaDrug Announces Proposed Issuance of Debenture Units
October 31, 2024
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
October 31, 2024
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
September 19, 2024
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
August 19, 2024
Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine
May 23, 2024
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
May 13, 2024
PharmaDrug Announces Director Appointment and Resignation
May 2, 2024
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 1, 2024
PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
April 16, 2024
PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
March 13, 2024
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
February 27, 2024
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
February 14, 2024
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
February 12, 2024
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
February 8, 2024
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
February 1, 2024